SCHEMBL91552

SCHEMBL91552

Cc1cc(Cl)c(NC(=O)c2cn(C)c3cccc(F)c23)cc1Cl

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.44
KMT2A Q03164 2/20 0.44
MEN1 O00255 1/20 0.44
TP53 P04637 1/20 0.44
MAPT P10636 1/20 0.44
POLB P06746 1/20 0.41
LMNA P02545 3/20 0.41
KDM4E B2RXH2 2/20 0.41
MAOB P27338 3/20 0.40
RAB9A P51151 2/20 0.40
NPC1 O15118 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
RORC P51449 2/20 0.40
TRPV1 Q8NER1 1/20 0.39
RXFP1 Q9HBX9 1/20 0.39
P2RX7 Q99572 1/20 0.38
MALT1 Q9UDY8 1/20 0.38
GAA P10253 1/20 0.37
ITGB1 P05556 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL92572 0.93 ALDH1A1 (0.44) ALDH1A1KMT2AMEN1TP53MAPT
SCHEMBL91553 0.82 PCSK9 (0.42) ALDH1A1KMT2AMEN1TP53MAPT
SCHEMBL27596561 0.82 POLB (0.43) ALDH1A1KMT2AMEN1TP53MAPT
SCHEMBL2432198 0.82 ITGB1 (0.48) ALDH1A1KMT2AMEN1TP53MAPT
SCHEMBL91608 0.81 MAOB (0.54) ALDH1A1KMT2AMEN1MAPTPOLB
SCHEMBL14491710 0.80 ITGB1 (0.47) ALDH1A1KMT2AMEN1TP53MAPT
SCHEMBL14626863 0.80 ITGB1 (0.43) ALDH1A1KMT2AMEN1TP53MAPT
SCHEMBL2433088 0.79 TP53 (0.38) ALDH1A1KMT2AMEN1TP53MAPT
SCHEMBL91539 0.79 MAPT (0.42) ALDH1A1TP53MAPTPOLBLMNA
SCHEMBL91603 0.79 MAOB (0.51) ALDH1A1KMT2AMEN1MAPTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130065882-A1 VLA-4 inhibitory drug MACHINAGA NOBUO (JP) 2013-03-14 US disclosed
US-20120157437-A1 VLA-4 INHIBITORY DRUG DAIICHI SANKYO COMPANY, LIMITED (JP) 2012-06-21 US disclosed
US-8129366-B2 VLA-4 inhibitory drug DAIICHI SANKYO COMPANY, LIMITED (JP) 2012-03-06 US disclosed
US-20090233901-A1 VLA-4 INHIBITORY DRUG DAIICHI SANKYO COMPANY, LIMITED (JP) 2009-09-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120157437-A1 VLA-4 INHIBITORY DRUG VCAM1, ITGB4, ITGA4 ALDH1A1 216/4885KMT2A 568/4885MEN1 4254/4885
US-20130065882-A1 VLA-4 inhibitory drug VCAM1, ITGB4, ITGA4 ALDH1A1 207/4885KMT2A 656/4885MEN1 4337/4885
US-20090233901-A1 VLA-4 INHIBITORY DRUG VCAM1, ITGB4, ITGA4 ALDH1A1 525/4885KMT2A 881/4885MEN1 4226/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.